Interview with Dr. Adil Rasheed—Winner of the Biomedicines Young Investigator Award
Dr. Adil Rasheed is an Assistant Professor at Augusta University, USA, within the Immunology Center of Georgia. Dr. Rasheed started his lab in November 2023, where his group focuses on immunometabolic contributions to cardiovascular diseases, specifically atherosclerosis.
The following is a short interview with Dr. Adil Rasheed:
1. Could you please briefly introduce yourself to the readers?
I earned my PhD in 2017 from the University of Toronto, where I explored the role of liver X receptors as pharmacological agents to enhance the formation and function of endothelial progenitor cells, promoting vascular repair in conditions like diabetes and atherosclerosis. Following this, I completed a postdoctoral fellowship at the University of Ottawa Heart Institute. There, my research focused on the local and peripheral impact of immunometabolic factors in driving atherosclerotic plaque development. This experience sparked my deep interest in understanding the underlying mechanisms contributing to plaque progression, particularly with the goal of targeting dysregulated factors and pathways to discover innovative therapeutic strategies for patients with established disease.
2. Could you please share your current research direction and latest progress?
Our lab is currently exploring several exciting research directions, with one that stands out as particularly promising. We are delving deeper into the role of immunometabolic factors in atherogenesis, investigating how these factors exhibit stage-specific functions that cannot be easily categorized as “good” or “bad”. A major focus of our work is understanding the mechanisms that drive the transition between these functional states. More importantly, we are working to harness this biological knowledge to promote the beneficial effects of these factors while minimizing their negative impacts, which could open new therapeutic possibilities for cardiovascular diseases.
3. Could you please share with us your feelings after winning the award?
I am truly honored to have been selected for this award. The application process was especially meaningful, as it required me to step back and reflect on my entire scientific journey, rather than simply summarizing a specific project, as one would for a conference abstract. It provided an invaluable opportunity to consider how my past work has shaped my current research focus. This experience serves as an important reminder, both to myself and to my lab, to keep sight of the bigger picture and the broader impact of our research. It makes the work we do all the more fulfilling and motivating.
4. Could you please share the most impressive breakthrough in your research career, either in terms of ideas or research results?
One of the most rewarding moments in my research career has been transforming a bold idea into a proven concept. Early on, I hypothesized that we could enhance the functionality of endothelial progenitor cells from patients with established coronary artery disease, potentially opening the door to new cell-autologous therapies for these individuals. This hypothesis was later validated through our research, culminating in my first author manuscript as a graduate student. This breakthrough not only marked a significant scientific achievement but also served as a pivotal milestone in my development as a researcher, solidifying my passion for exploring innovative therapeutic strategies.
5. Do you have any other suggestions for how journals and publishers can further support young researchers and the academic community?
Opportunities like this one are a prime example of how journals can leverage their platforms to elevate the voices of early-career researchers and increase their international visibility. By providing more avenues for young investigators to showcase their work, journals can play a pivotal role in nurturing the next generation of scientific leaders and fostering a more dynamic academic community.
6. Based on your experience, which research topics in this field do you think will be of particular interest to the academic community in the next few years?
One area that particularly excites me is the evolving field of gene editing therapies for cardiometabolic diseases. Additionally, I believe that advancing anti-inflammatory therapies for patients with cardiovascular disease—especially those who have already achieved maximal lipid lowering—has the potential to significantly reduce mortality rates. This aligns with my strong belief that diseases like atherosclerosis must be tackled from multiple angles to achieve meaningful progress in patient outcomes. These areas represent exciting frontiers that could greatly impact the future of cardiovascular medicine.
7. Do you have anything to say to your fellow scholars?
I encourage my fellow scholars to seize every opportunity that comes their way. Each experience, whether big or small, can offer valuable insights and contribute to your growth as a researcher.